-
公开(公告)号：WO2011133751A3
公开(公告)日：2012-01-12
申请号：PCT/US2011033396
申请日：2011-04-21
Applicant: VERTEX PHARMA , TANOURY GERALD J , HARRISON CRISTIAN , LITTLER BENJAMIN JOSEPH , ROSE PETER JAMISON , HUGHES ROBERT MICHAEL , JUNG YOUNG CHUN , SIESEL DAVID ANDREW , LEE ELAINE CHUNGMIN , BELMONT DANIEL T
Inventor： TANOURY GERALD J , HARRISON CRISTIAN , LITTLER BENJAMIN JOSEPH , ROSE PETER JAMISON , HUGHES ROBERT MICHAEL , JUNG YOUNG CHUN , SIESEL DAVID ANDREW , LEE ELAINE CHUNGMIN , BELMONT DANIEL T
IPC: C07D209/12 , C07D317/60 , C07D405/12
CPC classification number: C07D317/46 , C07C209/74 , C07C225/06 , C07D209/12 , C07D317/60 , C07D405/12
Abstract: The present invention features processes for preparing compounds, such as (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2- (1 -hydroxy-2-methylpropan-2-yl)- 1H-indol-5 -yl)cyclopropanecarboxamide (Compound 1 ), useful for treating CFTR mediated diseases such as cystic fibrosis.
Abstract translation: 本发明的特征在于制备化合物如（R）-1-（2,2-二氟苯并[d] [1,3]间二氧杂环戊烯-5-基）-N-（1-（2,3-二羟基丙基） -6-氟-2-（1-羟基-2-甲基丙-2-基）-1H-吲哚-5-基）环丙烷甲酰胺（化合物1），可用于治疗CFTR介导的疾病如囊性纤维化。
-
公开(公告)号：WO2011133751A9
公开(公告)日：2012-02-16
申请号：PCT/US2011033396
申请日：2011-04-21
Applicant: VERTEX PHARMA , TANOURY GERALD J , HARRISON CRISTIAN , LITTLER BENJAMIN JOSEPH , ROSE PETER JAMISON , HUGHES ROBERT MICHAEL , JUNG YOUNG CHUN , SIESEL DAVID ANDREW , LEE ELAINE CHUNGMIN , BELMONT DANIEL T
Inventor： TANOURY GERALD J , HARRISON CRISTIAN , LITTLER BENJAMIN JOSEPH , ROSE PETER JAMISON , HUGHES ROBERT MICHAEL , JUNG YOUNG CHUN , SIESEL DAVID ANDREW , LEE ELAINE CHUNGMIN , BELMONT DANIEL T
IPC: C07D209/12 , C07D317/60 , C07D405/12
CPC classification number: C07D317/46 , C07C209/74 , C07C225/06 , C07D209/12 , C07D317/60 , C07D405/12
Abstract: The present invention features processes for preparing compounds, such as (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2- (1 -hydroxy-2-methylpropan-2-yl)- 1H-indol-5 -yl)cyclopropanecarboxamide (Compound 1 ), useful for treating CFTR mediated diseases such as cystic fibrosis.
Abstract translation: （R）-1-（2,2-二氟苯并[d] [1,3]间二氧杂环戊烯-5-基）-N-（1-（2,3-二羟基丙基） -6-氟-2-（1-羟基-2-甲基丙烷-2-基）-1H-吲哚-5-基）环丙烷甲酰胺（化合物1），用于治疗CFTR介导的疾病如囊性纤维化。
-
公开(公告)号：WO2013006634A9
公开(公告)日：2013-03-21
申请号：PCT/US2012045431
申请日：2012-07-03
Applicant: VERTEX PHARMA , TANOURY GERALD J , JUNG YOUNG CHUN , MAGDZIAK DEREK , LOOKER ADAM
Inventor： TANOURY GERALD J , JUNG YOUNG CHUN , MAGDZIAK DEREK , LOOKER ADAM
IPC: C07D471/04
CPC classification number: C07D471/04 , C07B2200/13 , C07D239/42 , C07F5/025 , C07F5/04
Abstract: The present invention relates to processes and intermediates for the preparation of compounds useful as inhibitors of Janus kinases (JAK).
Abstract translation: 本发明涉及用于制备可用作Janus激酶（JAK）抑制剂的化合物的方法和中间体。
-
公开(公告)号：WO2007109080A3
公开(公告)日：2007-11-15
申请号：PCT/US2007006493
申请日：2007-03-14
Applicant: VERTEX PHARMA , PERNI ROBERT B , CHEN MINZHANG , JUNG YOUNG CHUN , FORSLUND RAYMOND E , TANOURY GERALD J , BENNANI YOUSSEF , ZLOKARNIK GREGOR , MALTAIS FRANCOIS
Inventor： PERNI ROBERT B , CHEN MINZHANG , JUNG YOUNG CHUN , FORSLUND RAYMOND E , TANOURY GERALD J , BENNANI YOUSSEF , ZLOKARNIK GREGOR , MALTAIS FRANCOIS
IPC: C07C231/20 , A61K31/403 , A61K31/422 , A61K31/498 , A61P31/12 , C07C237/04 , C07D209/52 , C07D403/12 , C07D403/14 , C07D498/10
CPC classification number: C07C231/20 , C07B2200/05 , C07B2200/07 , C07C237/04 , C07C2601/02 , C07D209/52 , C07D301/14 , C07D303/48 , C07D401/14 , C07D403/12 , C07D403/14 , C07D498/10 , C07K5/0202 , C07K7/02
Abstract: A deuterated a-ketoamido steric specific compound of the formula (I), wherein D denotes a deuterium atom on a steric specific carbon atom.
Abstract translation: 式（I）的氘代α-酮酰胺基空间特异性化合物，其中D表示空间特异性碳原子上的氘原子。
-
公开(公告)号：WO2011153423A3
公开(公告)日：2013-03-07
申请号：PCT/US2011039049
申请日：2011-06-03
Applicant: VERTEX PHARMA , TANOURY GERALD J
Inventor： TANOURY GERALD J
IPC: C07D209/52 , C07D209/54
CPC classification number: C07K5/1016 , C07D209/52 , C07D209/54 , C07D498/10
Abstract: A process for preparing enantioselectively a compound of formula I-la or I-lb: over a compound of formulas 1-2 - 1-7
Abstract translation: 制备式I-1a或I-1b化合物对映体选择性的方法：在式1-2至1-7的化合物上
-
Patent Agency Ranking
公开(公告)号：WO2013006634A3
公开(公告)日：2013-05-10
申请号：PCT/US2012045431
申请日：2012-07-03
Applicant: VERTEX PHARMA , TANOURY GERALD J , JUNG YOUNG CHUN , MAGDZIAK DEREK , LOOKER ADAM , KLINE BILLIE J , JURCIK VACLAV , DOMINGUEZ OLMO BEATRIZ
Inventor： TANOURY GERALD J , JUNG YOUNG CHUN , MAGDZIAK DEREK , LOOKER ADAM , KLINE BILLIE J , JURCIK VACLAV , DOMINGUEZ OLMO BEATRIZ
IPC: C07D471/04
CPC classification number: C07D471/04 , C07B2200/13 , C07D239/42 , C07F5/025 , C07F5/04
Abstract: The present invention relates to processes and intermediates for the preparation of compounds useful as inhibitors of Janus kinases (JAK).
Abstract translation: 本发明涉及制备可用作Janus激酶（JAK）抑制剂的化合物的方法和中间体。
-
公开(公告)号：WO2007022459A2
公开(公告)日：2007-02-22
申请号：PCT/US2006032481
申请日：2006-08-18
Applicant: VERTEX PHARMA , TANOURY GERALD J , CHEN MINZHANG , COCHRAN JOHN E
Inventor： TANOURY GERALD J , CHEN MINZHANG , COCHRAN JOHN E
CPC classification number: C07K7/06 , C07D209/52 , C07K5/0812 , C07K7/02
Abstract: The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections.
Abstract translation: 本发明涉及可用于制备蛋白酶抑制剂，特别是丝氨酸蛋白酶抑制剂的化合物和方法。 蛋白酶抑制剂可用于治疗HCV感染。
-
公开(公告)号：WO2005090334A2
公开(公告)日：2005-09-29
申请号：PCT/US2005008251
申请日：2005-03-11
Applicant: VERTEX PHARMA , TANOURY GERALD J , CHEN MINZHANG , JONES ANDREW D , NYCE PHILIP L , TRUDEAU MARTIN , GUERIN DAVID J , SNOONIAN JOHN R
Inventor： TANOURY GERALD J , CHEN MINZHANG , JONES ANDREW D , NYCE PHILIP L , TRUDEAU MARTIN , GUERIN DAVID J , SNOONIAN JOHN R
IPC: C07B43/04 , C07B57/00 , C07D405/12 , C07D405/00
CPC classification number: C07D207/16 , C07D209/52 , C07D211/60 , C07D405/12 , C07D417/06 , C07D417/12 , C07D417/14 , Y02P20/55
Abstract: The invention relates to processes and compounds useful for producing modified aspartic acid derivatives, such as aspartic acid aldehyde moieties. Aspartic acid derivatives are useful for preparing caspase inhibitors and/or prodrugs thereof.
Abstract translation: 本发明涉及可用于生产改性天冬氨酸衍生物如天冬氨酸醛部分的方法和化合物。 天冬氨酸衍生物可用于制备半胱天冬酶抑制剂和/或其前药。
-
公开(公告)号：ES2843173T3
公开(公告)日：2021-07-16
申请号：ES18164040
申请日：2014-11-12
Applicant: VERTEX PHARMA
Inventor： TANOURY GERALD J , NUGENT WILLIAM , DVORNIKOVS VADIMS , ROSE PETER
IPC: C07D471/04 , C07C51/083
Abstract: Un método para preparar el compuesto (C) **(Ver fórmula)** o una sal farmacéuticamente aceptable del mismo, en donde R1 es etilo, que comprende: (g) hacer reaccionar el compuesto (A) **(Ver fórmula)** con quinina **(Ver fórmula)** y alcohol etílico para formar un aducto de la quinina y del compuesto (C-1) **(Ver fórmula)** (h) romper el aducto de quinina y de compuesto (C-1) tratando el aducto con HCl para formar el compuesto (C-1) o una sal farmacéuticamente aceptable del mismo; y (i) epimerizar el compuesto (C-1) o una sal farmacéuticamente aceptable del mismo para formar el compuesto (C): **(Ver fórmula)** o una sal farmacéuticamente aceptable del mismo.
-
公开(公告)号：HUE052178T2
公开(公告)日：2021-04-28
申请号：HUE18164040
申请日：2014-11-12
Applicant: VERTEX PHARMA
Inventor： TANOURY GERALD J , NUGENT WILLIAM , DVORNIKOVS VADIMS , ROSE PETER
-
-
-
-
-
-
-
-
-
Search Results
137
records
(took 0.031 seconds)
